Skip to Main Content
Qurgen Qurgen
Menu Button

Dec. 2022

Brand Icon
In December 2022, Suzhou Fuent Pharmaceutical Co., Ltd. (China subsidiary of Qurgen) completed its first round of financing of 125 million RMB. The funds will be used for the construction of a 2,700-square-meter GMP drug manufacture facility for Qurgen and Fuent’s Phase I study.

Recent important events

Mar. 2026
Qurgen announced that the blood and biopsy tissue testing results of a late-stage of ocular...
Learn More
Jan. 13, 2026
Dr. Chai Yan officially Joined Qurgen/Fuent (Qurgen’s primary China subsidiary) as Senior Vice President of...
Learn More